About InflammX Therapeutics
InflammX Therapeutics is a Healthcare company based in Tampa (United States) founded in 2005 by Colin Green. Developer of therapeutics for ophthalmic disorders. InflammX Therapeutics has raised $28.53 million across 2 funding rounds. Its chief executive, as recorded, is Brian Levy. InflammX Therapeutics offers products and services including Xiflamâ„¢. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is InflammX Therapeutics, Inc. Its competitors include Insitro, BridgeBio and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
InflammX Therapeutics was established in 2005 in Tampa, United States, within the biotechnology sector. Ophthalmic therapeutics are developed, with operations centered on inhibitors targeting inflammasome pathways. Xiflam is provided as an oral NLRP3 inhibitor designed to suppress pathological Cx43 hemichannels and regulate inflammasome activity. Emphasis is directed toward indications such as diabetic macular edema, age-related macular degeneration, and geographic atrophy.
- Headquarters Tampa, United States
- Founders Colin Green
- SectorsHealthcare
- Email••••••••
- Website inflammx.com
- Legal Name Inflammx Therapeutics, Inc.
- Total Equity Funding$28.53M (USD)
in 2 rounds
- Latest Funding Round$9.13M (USD), Series B
Jan 2021
Products & Services of InflammX Therapeutics
InflammX Therapeutics offers a comprehensive portfolio of products and services, including Xiflam™.
Oral small molecule inhibiting hemichannels for retinal disease treatment
Funding Insights of InflammX Therapeutics
InflammX Therapeutics has successfully raised a total of $28.53M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $9.13 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.53M
- Total Rounds 2
- Last Round Series B — $9.13M
- First Round $19.4M
(Jul 2012)
All 2 funding rounds of InflammX Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $9.13M | Series B | – | – | – |
| Jul 2012 | $19.4M | Series B | – | – | – |
People of InflammX Therapeutics
3 people are tracked at InflammX Therapeutics (3 in leadership).
| Name | Role | Group |
|---|---|---|
Colin Green | Co-Founder | Leadership |
Brian Levy | CEO | Leadership |
David Pool | Chief Operating & Financial Officer | Leadership |
Complete people profiles for InflammX Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InflammX Therapeutics
3 dated milestones of InflammX Therapeutics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded InflammX Therapeutics is founded.
- Funding First funding round of $19.4M.
- Funding Latest funding round, Series B, of $9.1M.
Competitors of InflammX Therapeutics
InflammX Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of InflammX Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as InflammX Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inflammx Therapeutics
Complete news archive for InflammX Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InflammX Therapeutics
InflammX Therapeutics was founded in 2005 and raised its 1st funding round 7 years after it was founded.
InflammX Therapeutics is headquartered in Tampa, United States. It is registered at Tampa, Florida, United States.
Brian Levy is the CEO of InflammX Therapeutics, as recorded in our data.
InflammX Therapeutics is a funded company, having raised a total of $28.53M across 2 funding rounds to date. The company's 1st funding round was a Series B of $19.4M, raised on Jul 2012.
InflammX Therapeutics was established in 2005 in Tampa, United States, within the biotechnology sector. Ophthalmic therapeutics are developed, with operations centered on inhibitors targeting inflammasome pathways. Xiflam is provided as an oral NLRP3 inhibitor designed to suppress pathological Cx43 hemichannels and regulate inflammasome activity. Emphasis is directed toward indications such as diabetic macular edema, age-related macular degeneration, and geographic atrophy.
InflammX Therapeutics's top competitors include BridgeBio, Forge Biologics and Insitro.
InflammX Therapeutics offers Xiflamâ„¢.
InflammX Therapeutics operates through Inflammx Therapeutics, Inc..